See the DrugPatentWatch profile for Mesalamine
Mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel diseases (IBD), primarily ulcerative colitis and Crohn's disease [1]. It functions as an anti-inflammatory agent, working locally in the colon to reduce inflammation [2].
How Does Mesalamine Work to Reduce Inflammation?
Mesalamine's precise mechanism of action is not fully understood, but it is believed to inhibit the production of prostaglandins and leukotrienes, which are inflammatory substances in the gut [2]. It may also act as an antioxidant and scavenge free radicals, further contributing to its anti-inflammatory effects within the intestinal lining [3].
What Are the Different Forms of Mesalamine Available?
Mesalamine is available in various formulations designed to deliver the active ingredient to different parts of the gastrointestinal tract. These include delayed-release tablets and capsules, extended-release capsules, suppositories, and enemas [4]. The choice of formulation depends on the location and severity of the inflammation [5].
What Conditions Does Mesalamine Treat?
The primary indication for mesalamine is the induction and maintenance of remission in mild to moderate ulcerative colitis [4]. It is also used to treat Crohn's disease, particularly inflammation in the colon [5].
What Are the Potential Side Effects of Mesalamine?
Common side effects associated with mesalamine include headache, nausea, diarrhea, abdominal pain, and rash [4]. Less common but more serious side effects can include kidney problems, liver issues, and severe allergic reactions [6]. Patients should report any new or worsening symptoms to their healthcare provider [6].
When Does Mesalamine Go Off-Patent?
The patent landscape for mesalamine is complex due to its long history and the development of various formulations and brand names. Many of the original patents for mesalamine have expired, allowing for the availability of generic versions [7]. However, specific formulations or delivery systems may have independent patent protection [7]. Information on patent expiry dates for specific mesalamine products can often be found on resources like DrugPatentWatch.com [7].
What Are Some Alternatives to Mesalamine for IBD Treatment?
Beyond mesalamine, other treatments for inflammatory bowel diseases include corticosteroids (like prednisone), immunomodulators (such as azathioprine and methotrexate), and biologic therapies (including TNF inhibitors like infliximab and adalimumab) [5]. The choice of treatment is individualized based on the specific IBD, its severity, and the patient's response to therapy [5].
How Does Mesalamine Compare to Other IBD Medications?
Mesalamine is generally considered a first-line treatment for mild to moderate ulcerative colitis due to its favorable safety profile and targeted action [5]. Compared to corticosteroids, it typically has fewer systemic side effects and is suitable for long-term use [5]. Biologic therapies are often reserved for more severe or refractory cases of IBD that do not respond to conventional treatments [5].
---
Sources
1. https://www.drugpatentwatch.com/
2. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Ulcerative Colitis.
3. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Crohn's Disease.
4. Mayo Clinic. (n.d.). Mesalamine.
5. Daugs, M., & Stange, E. F. (2018). Management of Ulcerative Colitis. Gastroenterology Clinics of North America, 47(3), 537–551.
6. U.S. Food and Drug Administration. (n.d.). Drug Safety Communications.
7. DrugPatentWatch.com. (n.d.). Mesalamine Patents.